Companies AstraZeneca

AstraZeneca

Dublin, Dublin, IRL

70,000 Total Employees

Year Founded: 1999

View Website

Similar Companies Hiring

Pfizer

Artificial Intelligence • Healthtech • Machine Learning • Natural Language Processing • Biotech • Pharmaceutical

19 Offices

121990 Employees

AstraZeneca Company Stability & Growth

Updated on January 06, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for AstraZeneca?

Strengths in revenue growth, market leadership (especially in oncology), and innovation-led approvals are accompanied by pricing and LOE headwinds, competitive pressure, and concentration risk in oncology. Together, these dynamics suggest a resilient near- to mid-term growth outlook that remains sensitive to policy, competition, and execution on late-stage delivery toward 2030.

Positive Themes About AstraZeneca

Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.
Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.
Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.

Considerations About AstraZeneca

Weak Market Position & Pricing Challenges: Pricing risk is elevated due to U.S. price negotiations and looming loss of exclusivity for key products, and strong competitors can pressure pricing and share even when clinical data are favorable. These factors could temper margins and growth in the medium term.
Undiversified Revenue Streams: Portfolio concentration in oncology increases exposure to trial outcomes, safety signals such as ADC‑related ILD, and label decisions.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.

Is This Your Company? Claim Profile